A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma) (2019)

Peer-Reviewed Study · Agrawal S, Vamadevan P, Mazibuko N, Bannister R, Swery R, Wilson S, Edwards S · June 27, 2019

Agrawal S et al., 2019-06-27: Perspective article describing the Care Oncology Clinic METRICS protocol of metformin, atorvastatin, doxycycline and mebendazole, with a retrospective analysis of 95 glioblastoma patients. It reported a median overall survival of 26.3 months for the whole cohort and 27.1 months for those on optimal standard of care, and was retracted in 2026.

The median OS for this unselected cohort of patients with GBM who received off-label medications alongside optimal SoC (i.e. surgery, chemotherapy and radiotherapy) was 27.1 months (95% CI 24.0; 37.6) from diagnosis, with a 2-year survival of 64.0%.

n/a

Agrawal S et al., 2019-06-27: Perspective article describing the Care Oncology Clinic METRICS protocol of metformin, atorvastatin, doxycycline and mebendazole, with a retrospective analysis of 95 glioblastoma patients. It reported a median overall survival of 26.3 months for the whole cohort and 27.1 months for those on optimal standard of care, and was retracted in 2026.